International Clinical and Medical Case Reports Journal
Case Report (ISSN: 2832-5788)

Cancer Survival Information and Cancer Prevalence in Europe

Alireza Heidari [1,2,3,4,5*]

[1]Department of Biology, Spelman College, 350 Spelman Lane Southwest, Atlanta, GA 30314, USA

[2]Faculty of Chemistry, California South University, 14731 Comet St. Irvine, CA 92604, USA

[3]BioSpectroscopy Core Research Laboratory (BCRL), California South University, 14731 Comet St. Irvine, CA 92604, USA

[4]Cancer Research Institute (CRI), California South University, 14731 Comet St. Irvine, CA 92604, USA

[5]American International Standards Institute (AISI), Irvine, CA 3800, USA

Citation: *Alireza Heidari. Cancer Survival Information and Cancer Prevalence in Europe. Int Clinc Med Case Rep Jour. 2025;4(7):1-28.*

Received Date: 14 June 2025**; Accepted Date:** 01 July 2025**; Published Date:** 17 July 2025

[*]**Corresponding author:** Alireza Heidari, Department of Biology, Spelman College, 350 Spelman Lane Southwest, Atlanta, GA 30314, USA

ABSTRACT

Statistics show that the chances of survival for cancer patients in Europe vary significantly between countries. These differences are linked to factors such as economic conditions, the quality of the healthcare system and access to health services. There are more than 12 million cancer survivors in Europe, including around 300,000 childhood cancer survivors who have been spared death thanks to advances in early detection, effective treatments and government support in the form of social security benefits.

Keywords: Cancer; Europe; Risk; Survival; European Union; Economic Conditions; Healthcare System; Health Services; Effective Treatments; Government Support; Social Security; European Countries

INTRODUCTION

Cancer was the second leading cause of death in the European Union in 2021, claiming more than one million lives, accounting for nearly 22% of all deaths in the region. Despite scientific advances and efforts to improve treatment and early detection, survival rates for patients still vary significantly depending on the type of cancer and the country in which they live. Survival rates refer to the percentage of people who survive a specific period of time after being diagnosed with cancer. This period is usually between one and five years [1-27]. A scientific report shows that the chances of cancer patients surviving vary significantly across European countries [28-45]. The report, published in the journal The Lancet in 2018, is part of the CONCORD–3 research project, led by Professor Alireza Heidari and a team of scientists at the Spelman College [151-164].

In 2020, nearly 2.7 million people in the European Union were diagnosed with cancer, and 1.3 million people, including more than 2,000 young people, died from complications of the disease [46-66]. The future outlook is more worrying. The results of forecasting models show that cancer cases will increase by 24% by 2035, making it the

leading cause of death for citizens of the European Union. However, studies show that around 40% of cancer cases are preventable [67-84]. For this reason, Europe's Beating Cancer Plan, with a budget of €4 billion, was launched in September 2022, based on the approach of more and better screening [85-99]. The European Commission therefore proposed to the 27 EU Member States to focus on early detection of cancers by increasing the number of screenings and testing among more target groups, and to detect more cancers [100-117]. Because early detection through screening can help save lives [118-135]. It is estimated that there are more than 12 million cancer survivors in Europe, including around 300,000 childhood cancer survivors who have been spared from death thanks to advances in early detection, effective treatments and government support in the form of social security benefits [136-150].

RESULTS AND DISCUSSION

According to the report, the average survival rate for lung cancer patients in the EU is only 15 percent. Bulgaria has the lowest survival rate at 7.7 percent, while Switzerland and Latvia have the highest survival rates at 20.4 percent. Germany has the best performance among major economies at 18.3 percent, while the UK remains below the EU average at 13.3 percent. For colorectal cancer, the average survival rate in the EU is 60 percent. Cyprus tops the list with 72.1 percent and Croatia comes in at the bottom with 51.1 percent. Among major European economies, Germany has the best performance at 64.8 percent and the UK has the worst performance at 60 percent. Prostate cancer is one of the types of cancer with the highest survival rates. The average survival rate in the EU is 87 percent, with Cyprus at the top with 99.2 percent. In contrast, Bulgaria has the lowest rate at 68.3 percent. In the case of breast cancer, the average survival rate in the EU is 82%. Cyprus performs best with 92.8%, while Lithuania and Romania are at the bottom with less than 75%. Stomach cancer, however, remains one of the cancers with the lowest survival rates. The average survival rate in the EU is only 27%. Belgium has the best figure with 37.5% and Bulgaria has the lowest figure with 16%. In the case of ovarian cancer, the average survival rate in the EU is 39.2%. Sweden tops the list with 46.5%, while Malta and Ireland have the lowest survival rates with less than a third (Figures 1 and 2).

Professor Alireza Heidari, an oncologist and biochemist, reported to National Institute of Cancer Research and Hospital (NICRH) about the reasons for the differences in cancer survival rates, explaining that the differences are due to the different nature of the cancers and their location in the body [151-169]. "The lethality of cancers varies depending on where in the body they develop and what organs are nearby," Heidari reported [170-189]. "For example, a brain tumor is more life–threatening to a patient than a tumor in the leg." He also stressed that these differences are not limited to the characteristics of the disease itself. Other factors, such as access to effective treatments and the stage at which the cancer is diagnosed, also play a role. "If cancer is detected early, patients have a better chance of survival. However, diagnosis at an advanced stage usually reduces the chance of survival," Heidari reported [190-208]. Heidari gave two key reasons for the differences in cancer survival rates across countries. The first, he explained, is the difference in the stage at which cancer is diagnosed. The stage at which cancer is diagnosed has a huge impact on survival chances, and the stage at which cancer is diagnosed varies from country to country. The second factor is access to advanced treatments [209-228]. For example, radiotherapy, which is used as an effective treatment for half of all cancers, is much more widely available in the wealthier countries of Western and Northern Europe. But in the less developed countries of Eastern and Southern Europe, it is more limited. Dr. Volker Arndt of the German Cancer

Research Centre (DKFZ) reported that the difference in cancer survival rates is linked to the capacity of the health system and how it is organized. “This difference is probably due to the capacity of the health system and how it is managed, including the waiting time for treatment,” he reported. Professor Alireza Heidari, one of the principal investigators of the CONCORD project, also stressed the key role of access to effective treatments [229–248]. He explained that while early detection of cancer is important, it cannot lead to the desired results without adequate access to advanced treatments. Heidari also warned that registering cancer–related data is facing problems, especially in Eastern European countries.

He stressed that many cancer registries in these regions face risks that could affect the quality and accuracy of data and harm research (Figures3-5) [249-264].



Figure 1: Schematic of most common types of cancer in the EU.



Figure 2: Schematic of types of cancer that kill the most people in the EU.



Figure 3: From January 2018 to December 2020, 83,795 new patients came to National Institute of Cancer Research and Hospital (NICRH) outpatient. Of them 35,733 (42.6%) had confirmed or provisional diagnosis of cancer.



Figure 4: Estimated number of cancer death worldwide in 2022, by type of cancer.



Figure 5: CRC screening rates by urbanization level, ages 50-74 years (year 2019). Source: EHIS, Eurostat [68].

CONCLUSIONS

The implementation of the Action Plan against Cancer is, of course, being pursued by the implementation of several complementary programs by the European Union to promote healthier lifestyles. Among them, given that lung cancer is by far the most common cause of cancer–related deaths, the "Tobacco–Free Generation" program, which seeks to reduce the proportion of the population that smokes and uses tobacco to 5% by 2040. There is also an effort to reduce harmful alcohol consumption by 10% by 2025, as well as reducing environmental pollution, in particular by improving air quality and reducing the number of people exposed to carcinogenic substances and radiation. Because official reports show that there is significant socio–economic inequalities in cancer mortality rates in EU member states. This inequality is partly due to differences in smoking rates, obesity, harmful alcohol consumption or air pollution. Of course, men, low–income people and those with low education levels are also more at risk of cancer than others (Table (1).

Accordingly, the European Commission supports Member States in achieving 90% coverage of the eligible population for breast, cervical and colorectal cancer screening by 2025. It also includes organized screening for lung, prostate and, in specific cases, stomach cancer. The target group for breast cancer screening is women aged 45 to 74 (compared to the previous age group of 50 to 69). Human papillomavirus (HPV) testing is recommended for women aged 30 to 65 every 5 years or more for cervical cancer detection, while promoting HPV vaccination status among girls and young women. Triage testing is also performed for colorectal cancer in people aged 50 to 74 by fecal immunochemical testing to determine the need for possible follow–up by endoscopy/colonoscopy. Organized screening for three other cancers is also being expanded: lung cancer testing for current and former smokers aged 50 to 75. Prostate cancer testing for men up to 70 years based on prostate–specific antigen testing and MRI. Helicobacter pylori screening and surveillance for precancerous gastric lesions in areas with high gastric cancer incidence and mortality (Table (2).

But to succeed in implementing the EU's "Banner on Cancer" plan, the EU must address the inequalities that exist among its member states. According to the plan, all citizens of the 27 EU member states should have the same right to high–quality care, diagnosis and treatment, equal access to medicines and an equal chance of survival. Official surveys show that in 2020, the coverage rate of preventive screenings in member states ranged from 84% in Denmark to 27% in Slovakia. At the same time, the number of people at risk also varied between member states, ranging from 6% to 90% for breast cancer and from 25% to 80% for cervical cancer. Survival rates after breast cancer treatment vary by up to 20% between member states, and five–year survival rates after colon cancer range from 49% to 68%. The EU has therefore started to design an EU platform to improve access to cancer medicines for citizens.

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022
Austria						5%	9%	17%	26%	35%	45%	53%	53%
Belgium				61%	63%	64%	66%	67%	68%	69%	69%	70%	70%
Bulgaria							21%	15%	8%	7%	9%	9%	9%
Cyprus									54%	59%	64%	64%	64%
Denmark	70%	73%	73%	77%	79%	80%	80%	76%	73%	75%	81%	82%	82%
Estonia										48%	59%	60%	60%
Finland					61%	62%	61%	69%	67%	67%	67%	67%	67%
France	25%	22%	17%	16%	13%	20%	21%	24%	24%	33%	37%	37%	42%
Germany	27%	27%	27%	29%	31%	33%	37%	40%	43%	47%	51%	54%	54%
Hungary								74%	72%	73%	71%	75%	80%
Ireland					68%	87%	87%	88%	75%	58%	66%	82%	83%
Italy	10%	38%	67%	67%	68%	72%	68%	66%	68%	62%	61%	69%	61%
Latvia					61%	51%	57%	49%	26%	34%	35%	38%	44%
Lithuania											33%	66%	71%
Luxembourg	43%	53%	41%	42%	47%	45%	43%	43%	43%	43%	43%	43%	43%
Malta							84%	78%	95%	83%	81%	79%	78%
Netherlands			55%	57%	57%	60%	63%	56%	51%	52%	52%	62%	66%
Portugal	92%	94%	97%	96%	96%	93%	72%	90%	92%	95%	97%	96%	94%
Slovenia					44%	45%	49%	38%	43%	39%	40%	42%	44%
Spain			58%	63%	69%	74%	73%	82%	87%	80%	76%	78%	86%
Sweden								78%	76%	75%	80%	84%	85%
EU average (of countries with data)	*45%*	*51%*	*54%*	*56%*	*58%*	*57%*	*56%*	*58%*	*57%*	*57%*	*58%*	*62%*	*64%*

Source: WHO immunisation database (21).

Table 1: HPV vaccination coverage by age 15, last dose, females, in the EU [21].

Country	Source
France	News link: https://www.connexionfrance.com/article/French-news/Health/France-to-roll-out-free-vaccine-for-sexually-transmitted-infection-HPV
Latvia	Mandatory for both girls and boys according to ECDC: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=38&SelectedCountryIdByDisease=115 News link: https://eng.lsm.lv/article/society/health/02.05.2023-hpv-vaccines-to-be-provided-for-all-adolescents-in-latvia.a507126/
Lithuania	News link: https://www.lrt.lt/en/news-in-english/19/1879495/lithuania-launches-hpv-vaccination-for-boys
Malta	https://www.maltatoday.com.mt/news/national/120570/boys_aged_12_to_be_offered_hpv_vaccine_as_well#.ZF4lkXZBw2w
Poland	https://pubmed.ncbi.nlm.nih.gov/37631939/
Romania	Boys up to 18 can receive free HPV vaccines, Romanian health minister says | Romania Insider (romania-insider.com)
Spain	https://www.isglobal.org/en/healthisglobal/-/custom-blog-portlet/-por-que-vacunar-a-los-ninos-contra-el-virus-del-papiloma-humano-vph-/9764198/0

Table 2: Countries that have or will include boys in the national HPV vaccination program during 2023.

ACKNOWLEDGEMENTS

This study was supported by the Cancer Research Institute (CRI) Project of Scientific Instrument and Equipment Development, the National Natural Science Foundation of the United States, the International Joint BioSpectroscopy Core Research Laboratory (BCRL) Program supported by the California South University (CSU), and the Key project supported by the American International Standards Institute (AISI), Irvine, California, USA. Also, the author would like to thank the medical and support staff of the cardiovascular treatment and recovery unit where this study was conducted, especially Sue Smith and James Sawyer. In addition, the author would like to acknowledge Katie Kanst for help with programming, Charles Yates for help with data processing, and all of the participants who took part in this study. We would also like to show our gratitude to the Spelman College for sharing their pearls of wisdom with us during the course of this research, and we thank reviewers for their so–called insights. We are also immensely grateful to Spelman College for their comments on an earlier version of the manuscript, although any errors are our own and should not tarnish the reputations of these esteemed persons. It should be noted that this study was completed while the author was on faculty at the Cancer Research Institute (CRI) of the California South University (CSU). The author would like to thank the patients and families who participated in this study at hospitals.

REFERENCES

1. European Commission. ECIS - European Cancer Information System. 2023 [2023-12-12].
2. European Commission. Europe's Beating Cancer Plan: Communication from the commission to the european parliament and the council. 2021.
3. European Commission. EU Mission: Cancer. 2023 [2023-08-16].
4. European Commission. European Cancer Inequalities Registry. 2022 [2023-07-11].
5. European Cancer Organisation. European Cancer Pulse. 2022 [2023-07-11].
6. Berwick D, Fox DM. "Evaluating the Quality of Medical Care": Donabedian's Classic Article 50 Years Later. Milbank Q. 2016;94(2):237-41.
7. Donabedian A. The quality of care. How can it be assessed? JAMA. 1988;260(12):1743-8.
8. Hofmarcher T, Brådvik G, Svedman C, Lindgren P, Jönsson B, Wilking N. Comparator Report on Cancer in Europe 2019 – Disease Burden, Costs and Access to Medicines. Lund: IHE, 2019.
9. Eloranta S, Smedby KE, Dickman PW, Andersson TM. Cancer survival statistics for patients and healthcare professionals - a tutorial of real-world data analysis. J Intern Med. 2021;289(1):12-28.
10. Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145-86.
11. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population- based registries in 71 countries. Lancet. 2018;391(10125):1023-75.

12. Loke AY, Kwan ML, Wong YT, Wong AKY. The Uptake of Human Papillomavirus Vaccination and Its Associated Factors Among Adolescents: A Systematic Review. J Prim Care Community Health. 2017;8(4):349-62.
13. Serrano B, Brotons M, Bosch FX, Bruni L. Epidemiology and burden of HPV-related disease. Best Pract Res Clin Obstet Gynaecol. 2018; 47:14-26.
14. World Health Organization (WHO). Cervical cancer: key facts. 2020 [2023-05-31].
15. European Cancer Organisation. A Four Step Plan for Eliminating HPV Cancers in Europe. 2020.
16. Kjaer SK, Nygård M, Sundström K, Dillner J, Tryggvadottir L, Munk C, et al. Final analysis of a 14-year long-term follow-up study of the effectiveness and immunogenicity of the quadrivalent human papillomavirus vaccine in women from four nordic countries. EClinicalMedicine. 2020; 23:100401.
17. World Health Organization (WHO). Human papillomavirus vaccines: WHO position paper, December 2022. 2022 [2023-06-15].
18. European Center for Disease Control and Prevention (ECDC). Vaccine Scheduler: Human Papillomavirus Infection: Recommended vaccinations. ECDC; 2023 [2023-06-01].
19. Euractiv. Poland last EU country to make HPV vaccine free of charge. 2023 [2023-08-28].
20. European Center for Disease Control and Prevention (ECDC). Guidance on HPV vaccination in EU countries: focus on boys, people living with HIV and 9-valent HPV vaccine introduction. 2020. INEQUALITIES IN CANCER CARE IN THE EU IHE REPORT 2024:1 54.
21. World Health Organization (WHO). Human Papillomavirus (HPV) vaccination coverage. [2023-10-09].
22. European Center for Disease Control and Prevention (ECDC). Introduction of HPV vaccines in European Union countries– an update. 2012.
23. Nguyen-Huu NH, Thilly N, Derrough T, Sdona E, Claudot F, Pulcini C, et al. Human papillomavirus vaccination coverage, policies, and practical implementation across Europe. Vaccine. 2020;38(6):1315-31.
24. Lebanova H, Stoev S, Naseva E, Getova V, Wang W, Sabale U, et al. Economic Burden of Cervical Cancer in Bulgaria. Int J Environ Res Public Health. 2023;20(3):2746.
25. Ministry of Health of the Czech Republic. Czech National Cancer Control Plan 2030 - Summary of analytical study. 2022.
26. Ministry of Health Romania. Plan National de Combatere a Cancerului. 2022.
27. Fernández de Casadevante V, Gil Cuesta J, Cantarero-Arévalo L. Determinants in the Uptake of the Human Papillomavirus Vaccine: A Systematic Review Based on European Studies. Front Oncol. 2015; 5:141.
28. Wemrell M, Vicente RP, Merlo J. Mapping sociodemographic and geographical differences in human papillomavirus non-vaccination among young girls in Sweden. Scand J Public Health. 2023;51(2):288-95.
29. Feiring B, Laake I, Molden T, Cappelen I, Håberg SE, Magnus P, et al. Do parental education and income matter? A nationwide register-based study on HPV vaccine uptake in the school-based immunisation programme in Norway. BMJ Open. 2015;5(5): e006422.
30. Corcoran B, Clarke A, Barrett T. Rapid response to HPV vaccination crisis in Ireland. Lancet. 2018;391(10135):2103.

31. Jean S, 3rd, Elshafei M, Buttenheim A. Social determinants of community-level human papillomavirus vaccination coverage in aschool-based vaccination programme. Sex Transm Infect. 2018;94(4):248-53.
32. Schülein S, Taylor KJ, König J, Claus M, Blettner M, Klug SJ. Factors influencing uptake of HPV vaccination among girls in Germany. BMC Public Health. 2016; 16:995.
33. Wemrell M, Gunnarsson L. Attitudes Toward HPV Vaccination in Sweden: A Survey Study. Front Public Health. 2022; 10:729497.
34. Karafillakis E, Simas C, Jarrett C, Verger P, Peretti-Watel P, Dib F, et al. HPV vaccination in a context of public mistrust and uncertainty: a systematic literature review of determinants of HPV vaccine hesitancy in Europe. Hum Vaccin Immunother. 2019;15(7-8):1615-27.
35. Bulgarian News Agency. Council of Ministers Adopts National Cancer Control Plan 2030. 2023 [2023-08-23].
36. Colzani E, Johansen K, Johnson H, Pastore Celentano L. Human papillomavirus vaccination in the European Union/European Economic Area and globally: a moral dilemma. Euro Surveill. 2021;26(50):2001659.
37. Riesen M, Konstantinoudis G, Lang P, Low N, Hatz C, Maeusezahl M, et al. Exploring variation in human papillomavirus vaccination uptake in Switzerland: a multilevel spatial analysis of a national vaccination coverage survey. BMJ Open. 2018;8(5): e021006.
38. Andreas Charalambous. Interview on the topic of HPV vaccination and inequalities. In: Andreas Pousette, Thomas Hofmarcher, editors. 2023.
39. University of Groningen. Study on guidance on methodologies to assess the performance of vaccination programmes. 2022 [2023-06-09].
40. Karafillakis E, Peretti-Watel P, Verger P, Chantler T, Larson HJ. 'I trust them because my mum trusts them': Exploring the role of trust in HPV vaccination decision-making among adolescent girls and their mothers in France. Vaccine. 2022;40(8):1090-7.
41. World Health Organization (WHO). Roadmap to accelerate the elimination of cervical cancer as a public health problem in the WHO European Region 2022–2030 2022. INEQUALITIES IN CANCER CARE IN THE EU IHE REPORT 2024:1 55.
42. World Health Organization (WHO). Health Promotion: Track 2: Health literacy and health behaviour. 2023 [2023-07-14].
43. Brega AG, Hamer MK, Albright K, Brach C, Saliba D, Abbey D, et al. Organizational Health Literacy: Quality Improvement Measures with Expert Consensus. Health Lit Res Pract. 2019;3(2): e127-e46.
44. Coughlin SS, Vernon M, Hatzigeorgiou C, George V. Health Literacy, Social Determinants of Health, and Disease Prevention and Control. J Environ Health Sci. 2020;6(1):3061.
45. Holden CE, Wheelwright S, Harle A, Wagland R. The role of health literacy in cancer care: A mixed studies systematic review. PLoS One. 2021;16(11): e0259815.
46. European Commission. Mission on Cancer: Implementation plan. 2021.
47. Mavundza EJ, Iwu-Jaja CJ, Wiyeh AB, Gausi B, Abdullahi LH, Halle-Ekane G, et al. A Systematic Review of Interventions to Improve HPV Vaccination Coverage. Vaccines (Basel). 2021;9(7):687.

48. European Commission. State of Vaccine Confidence in the EU. 2022.
49. Hansen PR, Schmidtblaicher M, Brewer NT. Resilience of HPV vaccine uptake in Denmark: Decline and recovery. Vaccine. 2020;38(7):1842-8.
50. European Cancer Organisation. Improving HPV Vaccine Uptake in Children, Adolescents, and Young Adults: An Umbrella Review of Interventions. 2020.
51. Ilozumba O, Schmidt P, Ket JCF, Jaspers M. Can mHealth interventions contribute to increased HPV vaccination uptake? A systematic review. Prev Med Rep. 2021; 21:101289.
52. Efua Sackey M, Markey K, Grealish A. Healthcare professional's promotional strategies in improving Human papillomavirus (HPV) vaccination uptake in adolescents: A systematic review. Vaccine. 2022;40(19):2656-66.
53. Digestive Cancers Europe. Roadmap for the Prevention and Treatment of Colorectal Cancer in Europe. 2020.
54. Zheng S, Schrijvers JJA, Greuter MJW, Kats-Ugurlu G, Lu W, de Bock GH. Effectiveness of Colorectal Cancer (CRC) Screening on All-Cause and CRC-Specific Mortality Reduction: A Systematic Review and Meta-Analysis. Cancers (Basel). 2023;15(7):1948.
55. Gini A, Jansen EEL, Zielonke N, Meester RGS, Senore C, Anttila A, et al. Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. Eur J Cancer. 2020; 127:224-35.
56. Shaukat A, Levin TR. Current and future colorectal cancer screening strategies. Nat Rev Gastroenterol Hepatol. 2022;19(8):521-31.
57. Ibarrondo O, Lizeaga G, Martinez-Llorente JM, Larranaga I, Soto-Gordoa M, Alvarez- Lopez I. Health care costs of breast, prostate, colorectal and lung cancer care by clinical stage and cost component. Gac Sanit. 2022;36(3):246-52.
58. Mariotto AB, Warren JL, Zeruto C, Coughlan D, Barrett MJ, Zhao L, et al. Cancer- Attributable Medical Costs for Colorectal Cancer Patients by Phases of Care: What Is the Effect of a Prior Cancer History? J Natl Cancer Inst Monogr. 2020;2020(55):22-30.
59. Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening - an overview. Best Pract Res Clin Gastroenterol. 2010;24(4):439-49.
60. Ran T, Cheng CY, Misselwitz B, Brenner H, Ubels J, Schlander M. Cost-Effectiveness of Colorectal Cancer Screening Strategies-A Systematic Review. Clin Gastroenterol Hepatol. 2019;17(10):1969-81. e15.
61. Council of the European Union. Council Recommendation of 2 December 2003 on cancer screening. 2003.
62. Segnan N, Patnick J, von Karsa L. European Guidelines for Quality Assurance in Colorectal Cancer Screening and Diagnosis. Luxembourg: Publications Office of the European Union, 2010.
63. Council of the European Union. Council Recommendation of 9 December 2022 on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC 2022/C 473/01. 2022.
64. European Commission - Directorate-General for Research and Innovation - Group of Chief Scientific Advisors. Cancer screening in the European Union. Luxembourg: Publications Office of the European Union, 2022. INEQUALITIES IN CANCER CARE IN THE EU IHE REPORT 2024:1 56.

65. European Commission. Council recommendation on cancer screening (update). 2023 [2023-06-15].
66. United European Gastroenterology (UEG). Colorectal Screening Across Europe. 2019.
67. OECD/European Union. Health at a Glance: Europe 2022: State of Health in the EU Cycle. Paris: OECD Publishing, 2022.
68. Self-reported last colorectal cancer screening test by sex, age and educational attainment level [database on the Internet]. 2019.
69. Unanue-Arza S, Solís-Ibinagagoitia M, Díaz-Seoane M, Mosquera-Metcalfe I, Idigoras I, Bilbao I, et al. Inequalities and risk factors related to non-participation in colorectal cancer screening programmes: a systematic review. Eur J Public Health. 2021;31(2):346-55.
70. Klabunde C, Blom J, Bulliard JL, Garcia M, Hagoel L, Mai V, et al. Participation rates for organized colorectal cancer screening programmes: an international comparison. J Med Screen. 2015;22(3):119-26.
71. Nielsen JB, Berg-Beckhoff G, Leppin A. To do or not to do - a survey study on factors associated with participating in the Danish screening program for colorectal cancer. BMC Health Serv Res. 2021;21(1):43.
72. van de Schootbrugge-Vandermeer HJ, Lansdorp-Vogelaar I, de Jonge L, van Vuuren AJ, Dekker E, Spaander MCW, et al. Socio-demographic and cultural factors related to non-participation in the Dutch colorectal cancer screening programme. Eur J Cancer. 2023; 190:112942.
73. Artama M, Heinävaara S, Sarkeala T, Prättälä R, Pukkala E, Malila N. Determinants of non-participation in a mass screening program for colorectal cancer in Finland. Acta Oncol. 2016;55(7):870-4.
74. Bozhar H, McKee M, Spadea T, Veerus P, Heinävaara S, Anttila A, et al. Socio-economic inequality of utilization of cancer testing in Europe: A cross-sectional study. Prev Med Rep. 2022; 26:101733.
75. Berthelsen M, Berstad P, Randel KR, Hoff G, Natvig E, Holme Ø, et al. The impact of driving time on participation in colorectal cancer screening with sigmoidoscopy and faecal immunochemical blood test. Cancer Epidemiol. 2022; 80:102244.
76. Dupont-Lucas C, Dejardin O, Dancourt V, Launay L, Launoy G, Guittet L. Socio- geographical determinants of colonoscopy uptake after faecal occult blood test. Dig Liver Dis. 2011;43(9):714-20.
77. de Klerk CM, van der Vlugt M, Smagge BA, Toes-Zoutendijk E, Lansdorp-Vogelaar I, Dekker E, et al. Urban density differences in colorectal cancer screening participation and screening yield in The Netherlands. Prev Med Rep. 2022; 27:101791.
78. Katz ML, Reiter PL, Young GS, Pennell ML, Tatum CM, Paskett ED. Adherence to Multiple Cancer Screening Tests among Women Living in Appalachia Ohio. Cancer Epidemiol Biomarkers Prev. 2015;24(10):1489-94.
79. Gartlehner G, Schernhammer E, Lax SF, Preusser M, Bachler H, Tietzer H, et al. Screening for colorectal cancer. Wiener klinische Wochenschrift. 2023.
80. Federal Joint Committee. Directive on organized cancer screening programs. 2020 [2023-07-05].
81. Errea M, Skedgel C, Zamora B, Hampson G, Althin R, Hofmarcher T, et al. Opportunities to Increase Efficiency in Healthcare. OHE Contract Research, 2020.

82. Rat C, Latour C, Rousseau R, Gaultier A, Pogu C, Edwards A, et al. Interventions to increase uptake of faecal tests for colorectal cancer screening: a systematic review. Eur J Cancer Prev. 2018;27(3):227-36.
83. Issaka RB, Avila P, Whitaker E, Bent S, Somsouk M. Population health interventions to improve colorectal cancer screening by fecal immunochemical tests: A systematic review. Prev Med. 2019; 118:113-21.
84. Toes-Zoutendijk E, Portillo I, Hoeck S, de Brabander I, Perrin P, Dubois C, et al. Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. J Med Screen. 2020;27(2):68-76.
85. de Bekker-Grob EW, Donkers B, Veldwijk J, Jonker MF, Buis S, Huisman J, et al. What Factors Influence Non-Participation Most in Colorectal Cancer Screening? A Discrete Choice Experiment. Patient. 2021;14(2):269-81.
86. Berg-Beckhoff G, Leppin A, Nielsen JB. Reasons for participation and non-participation in colorectal cancer screening. Public Health. 2022; 205:83-9. INEQUALITIES IN CANCER CARE IN THE EU IHE REPORT 2024:1 57.
87. Moutel G, Duchange N, Lievre A, Orgerie MB, Jullian O, Sancho-Garnier H, et al. Low participation in organized colorectal cancer screening in France: underlying ethical issues. Eur J Cancer Prev. 2019;28(1):27-32.
88. Digestive Cancers Europe. Colorectal cancer screening in Europe: Saving Lives & Saving Money. 2019.
89. Facciorusso A, Demb J, Mohan BP, Gupta S, Singh S. Addition of Financial Incentives to Mailed Outreach for Promoting Colorectal Cancer Screening: A Systematic Review and Meta-analysis. JAMA Netw Open. 2021;4(8): e2122581.
90. Liles EG, Coronado GD, Perrin N, Harte AH, Nungesser R, Quigley N, et al. Uptake of a colorectal cancer screening blood test is higher than of a fecal test offered in clinic: A randomized trial. Cancer Treatment and Research Communications. 2017; 10:27-31.
91. Mauri G, Vitiello PP, Sogari A, Crisafulli G, Sartore-Bianchi A, Marsoni S, et al. Liquid biopsies to monitor and direct cancer treatment in colorectal cancer. British Journal of Cancer. 2022;127(3):394-407.
92. Zhou H, Zhu L, Song J, Wang G, Li P, Li W, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022;21(1):86.
93. Portillo I, Arana-Arri E, Gutiérrez-Ibarluzea I, Bilbao I, Luis Hurtado J, Sarasqueta C, et al. Factors related to the participation and detection of lesions in colorectal cancer screening programme-based faecal immunochemical test. Eur J Public Health. 2018;28(6):1143-8.
94. Mateo J, Steuten L, Aftimos P, André F, Davies M, Garralda E, et al. Delivering precision oncology to patients with cancer. Nat Med. 2022;28(4):658-65.
95. The London School of Economics and Political Science (LSE). Access to Personalised Oncology in Europe. 2020.
96. Malone ER, Oliva M, Sabatini PJB, Stockley TL, Siu LL. Molecular profiling for precision cancer therapies. Genome Med. 2020;12(1):8.

97. Mateo J, Chakravarty D, Dienstmann R, Jezdic S, Gonzalez-Perez A, Lopez-Bigas N, et al. A framework to rank genomic alterations as targets for cancer precision medicine: the ESMO Scale for Clinical Actionability of molecular Targets (ESCAT). Ann Oncol. 2018;29(9):1895-902.
98. Mosele F, Remon J, Mateo J, Westphalen CB, Barlesi F, Lolkema MP, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Ann Oncol. 2020;31(11):1491-505.
99. Normanno N, Apostolidis K, Wolf A, Al Dieri R, Deans Z, Fairley J, et al. Access and quality of biomarker testing for precision oncology in Europe. Eur J Cancer. 2022; 176:70-7.
100. Horgan D, Curigliano G, Rieß O, Hofman P, Büttner R, Conte P, et al. Identifying the Steps Required to Effectively Implement Next-Generation Sequencing in Oncology at a National Level in Europe. J Pers Med. 2022;12(1):72.
101. IQN Path & European Cancer Patient Coalition (ECPC) & European Federation of Pharmaceutical Industries and Associations (EFPIA). Unlocking the potential of precision medicine in Europe. 2021.
102. Ryska A, Berzinec P, Brcic L, Cufer T, Dziadziuszko R, Gottfried M, et al. NSCLC molecular testing in Central and Eastern European countries. BMC Cancer. 2018;18(1):269.
103. Norris RP, Dew R, Sharp L, Greystoke A, Rice S, Johnell K, et al. Are there socio- economic inequalities in utilization of predictive biomarker tests and biological and precision therapies for cancer? A systematic review and meta-analysis. BMC Med. 2020;18(1):282.
104. Norris RP, Dew R, Greystoke A, Todd A, Sharp L. Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population- Based Cohort Study in a Publicly Funded Health Care System. J Thorac Oncol. 2023; 990-1002.
105. Bayle A, Bonastre J, Chaltiel D, Latino N, Rouleau E, Peters S, et al. ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. Ann Oncol. 2023; 34(10):934-45.
106. Märkl B, Füzesi L, Huss R, Bauer S, Schaller T. Number of pathologists in Germany: comparison with European countries, USA, and Canada. Virchows Arch. 2021;478(2):335-41.INEQUALITIES IN CANCER CARE IN THE EU IHE REPORT 2024:1 58.
107. Fioretos T, Wirta V, Cavelier L, Berglund E, Friedman M, Akhras M, et al. Implementing precision medicine in a regionally organized healthcare system in Sweden. Nat Med. 2022;28(10):1980-2.
108. Smeltzer MP, Wynes MW, Lantuejoul S, Soo R, Ramalingam SS, Varella-Garcia M, et al. The International Association for the Study of Lung Cancer Global Survey on Molecular Testing in Lung Cancer. J Thorac Oncol. 2020;15(9):1434-48.
109. Narayanasamy S, Markina V, Thorogood A, Blazkova A, Shabani M, Knoppers BM, et al. Genomic Sequencing Capacity, Data Retention, and Personal Access to Raw Data in Europe. Front Genet. 2020; 11:303.
110. Morash M, Mitchell H, Beltran H, Elemento O, Pathak J. The Role of Next-Generation Sequencing in Precision Medicine: A Review of Outcomes in Oncology. J Pers Med. 2018;8(3):30.

111. Carneiro A, Amaral TMS, Brandao M, Scheffler M, Bol K, Ferrara R, et al. Disparities in access to oncology clinical trials in Europe in the period 2009-2019. Annals of Oncology. 2020;31: S1196.
112. Hofmarcher T, Lindgren P, Wilking N. Diagnosed but not treated: How to improve patient access to advanced NSCLC treatment in Europe. Lund: IHE, 2022.
113. European Society for Medical Oncology (ESMO). Guidelines. 2023 [2023-08-29].
114. Planchard D, Popat S, Kerr K, Novello S, Smit EF, Faivre-Finn C, et al. Metastatic non- small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4): iv192-237.
115. Cherny NI, Dafni U, Bogaerts J, Latino NJ, Pentheroudakis G, Douillard JY, et al. ESMO-Magnitude of Clinical Benefit Scale version 1.1. Ann Oncol. 2017;28(10):2340-66.
116. Cherny NI, Sullivan R, Dafni U, Kerst JM, Sobrero A, Zielinski C, et al. A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). Ann Oncol. 2015;26(8):1547-73.
117. Bailey H, Lee A, Eccles L, Yuan Y, Burlison H, Forshaw C, et al. Treatment patterns and outcomes of patients with metastatic non-small cell lung cancer in five European countries: a real-world evidence survey. BMC Cancer. 2023;23(1):603.
118. Soares M, Antunes L, Redondo P, Borges M, Hermans R, Patel D, et al. Real-world treatment patterns and survival outcomes for advanced non-small cell lung cancer in the pre-immunotherapy era in Portugal: a retrospective analysis from the I-O Optimise initiative. BMC Pulm Med. 2020;20(1):240.
119. Sorensen JB, Horvat P, Rosenlund M, Kejs AM, Patel D, Juarez-Garcia A, et al. Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015): SCAN-LEAF study. Future Oncol. 2022;18(2):205-14.
120. Hofmarcher T, Lindgren P, Wilking N. Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe. J Cancer Policy. 2022; 34:100362.
121. Lung Cancer Europe. LuCE report on lung cancer: disparities in diagnosis, care and treatment access. 2017.
122. Lung Cancer Europe. 7th LuCE report on lung cancer: challenges in the care pathway and preferences of people with lung cancer in Europe. 2022.
123. Forrest LF, Adams J, Wareham H, Rubin G, White M. Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis. PLoS Med. 2013;10(2): e1001376.
124. Forrest LF, Adams J, White M, Rubin G. Factors associated with timeliness of post-primary care referral, diagnosis and treatment for lung cancer: population-based, data-linkage study. Br J Cancer. 2014;111(9):1843-51.
125. Beattie V, Boerckel W, Rigney M, O'Hagan K, Hennink M, Fox J. 209P_PR Understanding patient experience in Europe: The first global lung cancer coalition patient experience survey. J Thorac Oncol. 2021;16(4):S810-1.
126. Lung Cancer Europe. 5th LuCE report on lung cancer: Psychological and social impact of lung cancer. 2020.

127. Björk J, Lynøe N, Juth N. Are smokers less deserving of expensive treatment? A randomised controlled trial that goes beyond official values. BMC Med Ethics. 2015;16:28. INEQUALITIES IN CANCER CARE IN THE EU IHE REPORT 2024:1 59.
128. The London School of Economics and Political Science (LSE). Access to medicines in Europe: delays and challenges for timely patient access. 2021.
129. Cufer T, Ciuleanu TE, Berzinec P, Galffy G, Jakopovic M, Jassem J, et al. Access to Novel Drugs for Non-Small Cell Lung Cancer in Central and Southeastern Europe: A Central European Cooperative Oncology Group Analysis. Oncologist. 2020;25(3): e598-601.
130. European Federation of Pharmaceutical Industries and Associations (EFPIA). EFPIA Patients W.A.I.T. Indicator 2022 Survey. 2023.
131. European Federation of Pharmaceutical Industries and Associations (EFPIA). The root cause of unavailability and delay to innovative medicines: Reducing the time before patients have access to innovative medicines. 2023.
132. De Angelis R. Cancer Prevalence in Europe 2020: results from the EUROCARE-6 study. 2020.
133. European Cancer Patient Coalition. Right to Be Forgotten for Cancer Survivors. 2023 [2023-07-07].
134. International Agency for Research on Cancer (IARC). Cancer Today. 2020 [2023-08-23].
135. European Cancer Organisation. Achieving Quality of Life for All Cancer Patients and Survivors. 2020.
136. Scocca G, Meunier F. Towards an EU legislation on the right to be forgotten to access to financial services for cancer survivors. Eur J Cancer. 2022; 162:133-7.
137. Joseph Carreas Foundation. Jóvenes y leukemia: más allá de sobrevivir. 2022.
138. European Commission. Access to financial products for persons with a history of cancer in EU Member States. 2022.
139. Scocca G, Meunier F. A right to be forgotten for cancer survivors: A legal development expected to reflect the medical progress in the fight against cancer. Journal of Cancer Policy. 2020;25(100246).
140. European Parliament & Council. Directive (EU) 2023/2225 of the European Parliament and of the Council of 18 October 2023 on credit agreements for consumers and repealing Directive 2008/48/EC. 2023.
141. Meunier F. Ending discrimination against cancer survivors. 2023 [2023-12-12].
142. Euractiv. Czech health insurers agree to 'forget' cancer survivors' former diagnoses. 2023 [2023-11-21].
143. Insurance Ireland. Insurance Ireland Life Members to Introduce New Code of Practice for Cancer Survivors Seeking Mortgage Protection Insurance, 2023 [2023-08-24].
144. Françoise Meunier. Interview on the topic of equal access to financial services among cancer survivors. In: Andreas Pousette, Hofmarcher T, editors. 2023.
145. Osservatorio Malattie Rare. Oblio oncologico: approvata al Senato una legge dedicata. 2023 [2023-12-12].
146. Philenews. Cancer survivors granted 'right to be forgotten' after Parliament landmark legislation. 2023 [2024-01-03].
147. European Cancer Patient Coalition. Factsheet on the Right to be forgotten for cancer survivors in the EU National Legislations. 2020. INEQUALITIES IN CANCER CARE IN THE EU IHE REPORT 2024:1 60.

148. Insurance Europe. Consumer Credit Directive: Including right to be forgotten for persons with prior diagnosis would be bad for consumers. 2022 [2023-07-07].
149. Insurance Europe. The EC Beating Cancer Plan — reflections on the right to be forgotten (position paper). 2021.
150. Picot J. Droit à l'oubli pour les malades de cancers: un risque relatif pour les assurances. Assurances et gestion des risques / Insurance and Risk Management. 2017;84(3-4):153-63.
151. Heidari A, "Different High–Resolution Simulations of Medical, Medicinal, Clinical, Pharmaceutical and Therapeutics Oncology of Human Lung Cancer Translational Anti–Cancer Nano Drugs Delivery Treatment Process under Synchrotron and X–Ray Radiations", J Med Oncol. Vol. 1 No. 1: 1, 2017.
152. Heidari A, "A Modern Ethnomedicinal Technique for Transformation, Prevention and Treatment of Human Malignant Gliomas Tumors into Human Benign Gliomas Tumors under Synchrotron Radiation", Am J Ethnomed, Vol. 4 No. 1: 10, 2017.
153. Heidari A, "Active Targeted Nanoparticles for Anti–Cancer Nano Drugs Delivery across the Blood–Brain Barrier for Human Brain Cancer Treatment, Multiple Sclerosis (MS) and Alzheimer's Diseases Using Chemical Modifications of Anti–Cancer Nano Drugs or Drug–Nanoparticles through Zika Virus (ZIKV) Nanocarriers under Synchrotron Radiation", J Med Chem Toxicol, 2 (3): 1–5, 2017.
154. Heidari A, "Investigation of Medical, Medicinal, Clinical and Pharmaceutical Applications of Estradiol, Mestranol (Norlutin), Norethindrone (NET), Norethisterone Acetate (NETA), Norethisterone Enanthate (NETE) and Testosterone Nanoparticles as Biological Imaging, Cell Labeling, Anti–Microbial Agents and Anti–Cancer Nano Drugs in Nanomedicines Based Drug Delivery Systems for Anti–Cancer Targeting and Treatment", Parana Journal of Science and Education (PJSE)–v.3, n.4, (10–19) October 12, 2017.
155. Heidari A, "A Comparative Computational and Experimental Study on Different Vibrational Biospectroscopy Methods, Techniques and Applications for Human Cancer Cells in Tumor Tissues Simulation, Modeling, Research, Diagnosis and Treatment", Open J Anal Bioanal Chem 1 (1): 014–020, 2017.
156. Heidari A, "Combination of DNA/RNA Ligands and Linear/Non–Linear Visible–Synchrotron Radiation–Driven N–Doped Ordered Mesoporous Cadmium Oxide (CdO) Nanoparticles Photocatalysts Channels Resulted in an Interesting Synergistic Effect Enhancing Catalytic Anti–Cancer Activity", Enz Eng 6: 1, 2017.
157. Heidari A, "Modern Approaches in Designing Ferritin, Ferritin Light Chain, Transferrin, Beta–2 Transferrin and Bacterioferritin–Based Anti–Cancer Nano Drugs Encapsulating Nanosphere as DNA–Binding Proteins from Starved Cells (DPS)", Mod Appro Drug Des. 1 (1). MADD.000504. 2017.
158. Heidari A, "Potency of Human Interferon β–1a and Human Interferon β–1b in Enzymotherapy, Immunotherapy, Chemotherapy, Radiotherapy, Hormone Therapy and Targeted Therapy of Encephalomyelitis Disseminate/Multiple Sclerosis (MS) and Hepatitis A, B, C, D, E, F and G Virus Enter and Targets Liver Cells", J Proteomics Enzymol 6: 1, 2017.
159. Heidari A, "Transport Therapeutic Active Targeting of Human Brain Tumors Enable Anti–Cancer Nanodrugs Delivery across the Blood–Brain Barrier (BBB) to Treat Brain Diseases Using Nanoparticles and Nanocarriers under Synchrotron Radiation", J Pharm Pharmaceutics 4 (2): 1–5, 2017.

160. Heidari A, C. Brown, "Combinatorial Therapeutic Approaches to DNA/RNA and Benzylpenicillin (Penicillin G), Fluoxetine Hydrochloride (Prozac and Sarafem), Propofol (Diprivan), Acetylsalicylic Acid (ASA) (Aspirin), Naproxen Sodium (Aleve and Naprosyn) and Dextromethamphetamine Nanocapsules with Surface Conjugated DNA/RNA to Targeted Nano Drugs for Enhanced Anti–Cancer Efficacy and Targeted Cancer Therapy Using Nano Drugs Delivery Systems", Ann Adv Chem. 1 (2): 061-9, 2017.
161. Heidari A, "High–Resolution Simulations of Human Brain Cancer Translational Nano Drugs Delivery Treatment Process under Synchrotron Radiation", J Transl Res. 1 (1): 1-3, 2017.
162. Heidari A, "Investigation of Anti–Cancer Nano Drugs' Effects' Trend on Human Pancreas Cancer Cells and Tissues Prevention, Diagnosis and Treatment Process under Synchrotron and X–Ray Radiations with the Passage of Time Using Mathematica", Current Trends Anal Bioanal Chem, 1(1): 36-41, 2017.
163. Heidari A, "Pros and Cons Controversy on Molecular Imaging and Dynamics of Double–Standard DNA/RNA of Human Preserving Stem Cells–Binding Nano Molecules with Androgens/Anabolic Steroids (AAS) or Testosterone Derivatives through Tracking of Helium–4 Nucleus (Alpha Particle) Using Synchrotron Radiation", Arch Biotechnol Biomed. 1(1): 067-0100, 2017.
164. Heidari A, "Visualizing Metabolic Changes in Probing Human Cancer Cells and Tissues Metabolism Using Vivo 1H or Proton NMR, 13C NMR, 15N NMR and 31P NMR Spectroscopy and Self–Organizing Maps under Synchrotron Radiation", SOJ Mater Sci Eng 5 (2): 1-6, 2017.
165. Heidari A, "Cavity Ring–Down Spectroscopy (CRDS), Circular Dichroism Spectroscopy, Cold Vapour Atomic Fluorescence Spectroscopy and Correlation Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Enliven: Challenges Cancer Detect Ther 4 (2): e001, 2017.
166. Heidari A, "Laser Spectroscopy, Laser–Induced Breakdown Spectroscopy and Laser–Induced Plasma Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Int J Hepatol Gastroenterol, 3 (4): 079-84, 2017.
167. Heidari A,"Time–Resolved Spectroscopy and Time–Stretch Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Enliven: Pharmacovigilance and Drug Safety 4 (2): e001, 2017.
168. Heidari A, "Overview of the Role of Vitamins in Reducing Negative Effect of Decapeptyl (Triptorelin Acetate or Pamoate Salts) on Prostate Cancer Cells and Tissues in Prostate Cancer Treatment Process through Transformation of Malignant Prostate Tumors into Benign Prostate Tumors under Synchrotron Radiation", Open J Anal Bioanal Chem 1(1): 021-6, 2017.
169. Heidari A, "Electron Phenomenological Spectroscopy, Electron Paramagnetic Resonance (EPR) Spectroscopy and Electron Spin Resonance (ESR) Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Austin J Anal Pharm Chem. 4 (3): 1091, 2017.
170. Heidari A, "Therapeutic Nanomedicine Different High–Resolution Experimental Images and Computational Simulations for Human Brain Cancer Cells and Tissues Using Nanocarriers Deliver DNA/RNA to Brain

Tumors under Synchrotron Radiation with the Passage of Time Using Mathematica and MATLAB", Madridge J Nano Tech. Sci. 2(2): 77-83, 2017.

171. Heidari A, "A Consensus and Prospective Study on Restoring Cadmium Oxide (CdO) Nanoparticles Sensitivity in Recurrent Ovarian Cancer by Extending the Cadmium Oxide (CdO) Nanoparticles–Free Interval Using Synchrotron Radiation Therapy as Antibody–Drug Conjugate for the Treatment of Limited–Stage Small Cell Diverse Epithelial Cancers", Cancer Clin Res Rep, 1: 2, e001, 2017.
172. Heidari A, "A Novel and Modern Experimental Imaging and Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under White Synchrotron Radiation", Cancer Sci Res Open Access 4 (2): 1-8, 2017.
173. Heidari A, "Different High–Resolution Simulations of Medical, Medicinal, Clinical, Pharmaceutical and Therapeutics Oncology of Human Breast Cancer Translational Nano Drugs Delivery Treatment Process under Synchrotron and X–Ray Radiations", J Oral Cancer Res 1 (1): 12-17, 2017.
174. Heidari A, "Vibrational Decihertz (dHz), Centihertz (cHz), Millihertz (mHz), Microhertz (μHz), Nanohertz (nHz), Picohertz (pHz), Femtohertz (fHz), Attohertz (aHz), Zeptohertz (zHz) and Yoctohertz (yHz) Imaging and Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", International Journal of Biomedicine, 7 (4), 335-40, 2017.
175. Heidari A, "Force Spectroscopy and Fluorescence Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", EC Cancer, 2 (5), 239-46, 2017.
176. Heidari A, "Photoacoustic Spectroscopy, Photoemission Spectroscopy and Photothermal Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", BAOJ Cancer Res Ther, 3: 3, 045-052, 2017.
177. Heidari A, "J–Spectroscopy, Exchange Spectroscopy (EXSY), Nucle¬ar Overhauser Effect Spectroscopy (NOESY) and Total Correlation Spectroscopy (TOCSY) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", EMS Eng Sci J, 1 (2): 006-13, 2017.
178. Heidari A, "Neutron Spin Echo Spectroscopy and Spin Noise Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Int J Biopharm Sci, 1: 103-07, 2017.
179. Heidari A, "Vibrational Decahertz (daHz), Hectohertz (hHz), Kilohertz (kHz), Megahertz (MHz), Gigahertz (GHz), Terahertz (THz), Petahertz (PHz), Exahertz (EHz), Zettahertz (ZHz) and Yottahertz (YHz) Imaging and Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Madridge J Anal Sci Instrum, 2 (1): 41-6, 2017.
180. Heidari A, "Two–Dimensional Infrared Correlation Spectroscopy, Linear Two–Dimensional Infrared Spectroscopy and Non–Linear Two–Dimensional Infrared Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", J Mater Sci Nanotechnol 6 (1): 101, 2018.

181. Heidari A, "Fourier Transform Infrared (FTIR) Spectroscopy, Near–Infrared Spectroscopy (NIRS) and Mid–Infrared Spectroscopy (MIRS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", Int J Nanotechnol Nanomed, Volume 3, Issue 1, Pages 1-6, 2018.
182. Heidari A, "Infrared Photo Dissociation Spectroscopy and Infrared Correlation Table Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", Austin Pharmacol Pharm, 3 (1): 1011, 2018.
183. Heidari A, "Novel and Transcendental Prevention, Diagnosis and Treatment Strategies for Investigation of Interaction among Human Blood Cancer Cells, Tissues, Tumors and Metastases with Synchrotron Radiation under Anti–Cancer Nano Drugs Delivery Efficacy Using MATLAB Modeling and Simulation", Madridge J Nov Drug Res, 1 (1): 18–24, 2017.
184. Heidari A, "Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Open Access J Trans Med Res, 2 (1): 00026–00032, 2018.
185. Gobato MPR, Gobato R, Heidari A. "Planting of Jaboticaba Trees for Landscape Repair of Degraded Area", Landscape Architecture and Regional Planning, Vol. 3, No. 1, Pages 1–9, 2018.
186. Heidari A, "Fluorescence Spectroscopy, Phosphorescence Spectroscopy and Luminescence Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", SM J Clin. Med. Imaging, 4 (1): 1018, 2018.
187. Heidari A, "Nuclear Inelastic Scattering Spectroscopy (NISS) and Nuclear Inelastic Absorption Spectroscopy (NIAS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Int J Pharm Sci, 2 (1): 1-14, 2018.
188. Heidari A, "X–Ray Diffraction (XRD), Powder X–Ray Diffraction (PXRD) and Energy–Dispersive X–Ray Diffraction (EDXRD) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", J Oncol Res; 2 (1): 1–14, 2018.
189. Heidari A, "Correlation Two–Dimensional Nuclear Magnetic Reso¬nance (NMR) (2D–NMR) (COSY) Imaging and Spectrosco¬py Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", EMS Can Sci, 1–1–001, 2018.
190. Heidari A, "Thermal Spectroscopy, Photothermal Spectroscopy, Thermal Microspectroscopy, Photothermal Microspectroscopy, Thermal Macrospectroscopy and Photothermal Macrospectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", SM J Biometrics Biostat, 3 (1): 1024, 2018.
191. Heidari A, "A Modern and Comprehensive Experimental Biospectroscopic Comparative Study on Human Common Cancers' Cells, Tissues and Tumors before and after Synchrotron Radiation Therapy", Open Acc J Oncol Med. 1 (1), 2018.
192. Heidari A, "Heteronuclear Correlation Experiments Such as Heteronuclear Single–Quantum Correlation Spectroscopy (HSQC), Heteronuclear Multiple–Quantum Correlation Spectroscopy (HMQC) and Heteronuclear Multiple–Bond Correlation Spectroscopy (HMBC) Comparative Study on Malignant and

Benign Human Endocrinology and Thyroid Cancer Cells and Tissues under Synchrotron Radiation", J Endocrinol Thyroid Res, 3 (1): 555603, 2018.

193. Heidari A, "Nuclear Resonance Vibrational Spectroscopy (NRVS), Nuclear Inelastic Scattering Spectroscopy (NISS), Nuclear Inelastic Absorption Spectroscopy (NIAS) and Nuclear Resonant Inelastic X–Ray Scattering Spectroscopy (NRIXSS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Int J Bioorg Chem Mol Biol. 6 (1e): 1–5, 2018.
194. Heidari A, "A Novel and Modern Experimental Approach to Vibrational Circular Dichroism Spectroscopy and Video Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under White and Monochromatic Synchrotron Radiation", Glob J Endocrinol Metab. 1 (3). GJEM. 000514-9, 2018.
195. Heidari A, "Pros and Cons Controversy on Heteronuclear Correlation Experiments Such as Heteronuclear Single–Quantum Correlation Spectroscopy (HSQC), Heteronuclear Multiple–Quantum Correlation Spectroscopy (HMQC) and Heteronuclear Multiple–Bond Correlation Spectroscopy (HMBC) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", EMS Pharma J. 1 (1): 002-08, 2018.
196. Heidari A, "A Modern Comparative and Comprehensive Experimental Biospectroscopic Study on Different Types of Infrared Spectroscopy of Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", J Analyt Molecul Tech. 3 (1): 8, 2018.
197. Heidari A, "Investigation of Cancer Types Using Synchrotron Technology for Proton Beam Therapy: An Experimental Biospectroscopic Comparative Study", European Modern Studies Journal, Vol. 2, No. 1, 13-29, 2018.
198. Heidari A, "Saturated Spectroscopy and Unsaturated Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Imaging J Clin Medical Sci. 5 (1): 001–7, 2018.
199. Heidari A, "Small–Angle Neutron Scattering (SANS) and Wide–Angle X–Ray Diffraction (WAXD) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Int J Bioorg Chem Mol Biol. 6 (2e): 1–6, 2018.
200. Heidari A, "Investigation of Bladder Cancer, Breast Cancer, Colorectal Cancer, Endometrial Cancer, Kidney Cancer, Leukemia, Liver, Lung Cancer, Melanoma, Non–Hodgkin Lymphoma, Pancreatic Cancer, Prostate Cancer, Thyroid Cancer and Non–Melanoma Skin Cancer Using Synchrotron Technology for Proton Beam Therapy: An Experimental Biospectroscopic Comparative Study", Ther Res Skin Dis 1 (1), 2018.
201. Heidari A, "Attenuated Total Reflectance Fourier Transform Infrared (ATR–FTIR) Spectroscopy, Micro–Attenuated Total Reflectance Fourier Transform Infrared (Micro–ATR–FTIR) Spectroscopy and Macro–Attenuated Total Reflectance Fourier Transform Infrared (Macro–ATR–FTIR) Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", International Journal of Chemistry Papers, 2 (1): 1-12, 2018.

202. Heidari A, "Mössbauer Spectroscopy, Mössbauer Emission Spectroscopy and 57Fe Mössbauer Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Acta Scientific Cancer Biology 2.3: 17-20, 2018.
203. Heidari A, "Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", Organic & Medicinal Chem IJ. 6 (1): 555676, 2018.
204. Heidari A, "Correlation Spectroscopy, Exclusive Correlation Spectroscopy and Total Correlation Spectroscopy Comparative Study on Malignant and Benign Human AIDS–Related Cancers Cells and Tissues with the Passage of Time under Synchrotron Radiation", Int J Bioanal Biomed. 2 (1): 001-7, 2018.
205. Heidari A, "Biomedical Instrumentation and Applications of Biospectroscopic Methods and Techniques in Malignant and Benign Human Cancer Cells and Tissues Studies under Synchrotron Radiation and Anti–Cancer Nano Drugs Delivery", Am J Nanotechnol Nanomed. 1 (1): 001-9, 2018.
206. Heidari A, "Vivo 1H or Proton NMR, 13C NMR, 15N NMR and 31P NMR Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Ann Biomet Biostat. 1 (1): 1001, 2018.
207. Heidari A, "Grazing–Incidence Small–Angle Neutron Scattering (GISANS) and Grazing–Incidence X–Ray Diffraction (GIXD) Comparative Study on Malignant and Benign Human Cancer Cells, Tissues and Tumors under Synchrotron Radiation", Ann Cardiovasc Surg. 1 (2): 1006, 2018.
208. Heidari A, "Adsorption Isotherms and Kinetics of Multi–Walled Carbon Nanotubes (MWCNTs), Boron Nitride Nanotubes (BNNTs), Amorphous Boron Nitride Nanotubes (a–BNNTs) and Hexagonal Boron Nitride Nanotubes (h–BNNTs) for Eliminating Carcinoma, Sarcoma, Lymphoma, Leukemia, Germ Cell Tumor and Blastoma Cancer Cells and Tissues", Clin Med Rev Case Rep 5: 201, 2018.
209. Heidari A, "Correlation Spectroscopy (COSY), Exclusive Correlation Spectroscopy (ECOSY), Total Correlation Spectroscopy (TOCSY), Incredible Natural–Abundance Double–Quantum Transfer Experiment (INADEQUATE), Heteronuclear Single–Quantum Correlation Spectroscopy (HSQC), Heteronuclear Multiple–Bond Correlation Spectroscopy (HMBC), Nuclear Overhauser Effect Spectroscopy (NOESY) and Rotating Frame Nuclear Overhauser Effect Spectroscopy (ROESY) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Acta Scientific Pharmaceutical Sciences 2.5: 30-5, 2018.
210. Heidari A, "Small–Angle X–Ray Scattering (SAXS), Ultra–Small Angle X–Ray Scattering (USAXS), Fluctuation X–Ray Scattering (FXS), Wide–Angle X–Ray Scattering (WAXS), Grazing–Incidence Small–Angle X–Ray Scattering (GISAXS), Grazing–Incidence Wide–Angle X–Ray Scattering (GIWAXS), Small–Angle Neutron Scattering (SANS), Grazing–Incidence Small–Angle Neutron Scattering (GISANS), X–Ray Diffraction (XRD), Powder X–Ray Diffraction (PXRD), Wide–Angle X–Ray Diffraction (WAXD), Grazing–Incidence X–Ray Diffraction (GIXD) and Energy–Dispersive X–Ray Diffraction (EDXRD) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Oncol Res Rev, Volume 1 (1): 1–10, 2018.

211. Heidari A, "Pump–Probe Spectroscopy and Transient Grating Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Adv Material Sci Engg, Volume 2, Issue 1, Pages 1–7, 2018.
212. Heidari A, "Grazing–Incidence Small–Angle X–Ray Scattering (GISAXS) and Grazing–Incidence Wide–Angle X–Ray Scattering (GIWAXS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Insights Pharmacol Pharm Sci 1 (1): 1–8, 2018.
213. Heidari A, "Acoustic Spectroscopy, Acoustic Resonance Spectroscopy and Auger Spectroscopy Comparative Study on Anti–Cancer Nano Drugs Delivery in Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Nanosci Technol 5 (1): 1–9, 2018.
214. Heidari A, "Niobium, Technetium, Ruthenium, Rhodium, Hafnium, Rhenium, Osmium and Iridium Ions Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Nanomed Nanotechnol, 3 (2): 000138, 2018.
215. Heidari A, "Homonuclear Correlation Experiments Such as Homonuclear Single–Quantum Correlation Spectroscopy (HSQC), Homonuclear Multiple–Quantum Correlation Spectroscopy (HMQC) and Homonuclear Multiple–Bond Correlation Spectroscopy (HMBC) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Austin J Proteomics Bioinform & Genomics. 5 (1): 1024, 2018.
216. Heidari A, "Atomic Force Microscopy Based Infrared (AFM–IR) Spectroscopy and Nuclear Resonance Vibrational Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", J Appl Biotechnol Bioeng. 5 (3): 142–148, 2018.
217. Heidari A, "Time–Dependent Vibrational Spectral Analysis of Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", J Cancer Oncol, 2 (2): 000124, 2018.
218. Heidari A, "Palauamine and Olympiadane Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Arc Org Inorg Chem Sci 3 (1), 2018.
219. Gobato R, Heidari A, "Infrared Spectrum and Sites of Action of Sanguinarine by Molecular Mechanics and Ab Initio Methods", International Journal of Atmospheric and Oceanic Sciences. Vol. 2, No. 1, pp. 1–9, 2018.
220. Heidari A, "Angelic Acid, Diabolic Acids, Draculin and Miraculin Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Med & Analy Chem Int J, 2 (1): 000111, 2018.
221. Heidari A, "Gamma Linolenic Methyl Ester, 5–Heptadeca–5,8,11–Trienyl 1,3,4–Oxadiazole–2–Thiol, Sulphoquinovosyl Diacyl Glycerol, Ruscogenin, Nocturnoside B, Protodioscine B, Parquisoside–B, Leiocarposide, Narangenin, 7–Methoxy Hespertin, Lupeol, Rosemariquinone, Rosmanol and Rosemadiol

Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Int J Pharma Anal Acta, 2 (1): 007-14, 2018.

222. Heidari A, "Fourier Transform Infrared (FTIR) Spectroscopy, Attenuated Total Reflectance Fourier Transform Infrared (ATR–FTIR) Spectroscopy, Micro–Attenuated Total Reflectance Fourier Transform Infrared (Micro–ATR–FTIR) Spectroscopy, Macro–Attenuated Total Reflectance Fourier Transform Infrared (Macro–ATR–FTIR) Spectroscopy, Two–Dimensional Infrared Correlation Spectroscopy, Linear Two–Dimensional Infrared Spectroscopy, Non–Linear Two–Dimensional Infrared Spectroscopy, Atomic Force Microscopy Based Infrared (AFM–IR) Spectroscopy, Infrared Photodissociation Spectroscopy, Infrared Correlation Table Spectroscopy, Near–Infrared Spectroscopy (NIRS), Mid–Infrared Spectroscopy (MIRS), Nuclear Resonance Vibrational Spectroscopy, Thermal Infrared Spectroscopy and Photothermal Infrared Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", Glob Imaging Insights, Volume 3 (2): 1-14, 2018.
223. Heidari A, "Heteronuclear Single–Quantum Correlation Spectroscopy (HSQC) and Heteronuclear Multiple–Bond Correlation Spectroscopy (HMBC) Comparative Study on Malignant and Benign Human Cancer Cells, Tissues and Tumors under Synchrotron and Synchrocyclotron Radiations", Chronicle of Medicine and Surgery 2.3: 144-56, 2018.
224. Heidari A, "Tetrakis [3, 5–bis (Trifluoromethyl) Phenyl] Borate (BARF)–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules", Medical Research and Clinical Case Reports 2.1: 113-26, 2018.
225. Heidari A, "Sydnone, Münchnone, Montréalone, Mogone, Montelukast, Quebecol and Palau'amine–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules", Sur Cas Stud Op Acc J. 1 (3), 2018.
226. Heidari A, "Fornacite, Orotic Acid, Rhamnetin, Sodium Ethyl Xanthate (SEX) and Spermine (Spermidine or Polyamine) Nanomolecules Incorporation into the Nanopolymeric Matrix (NPM)", International Journal of Biochemistry and Biomolecules, Vol. 4: Issue 1, Pages 1–19, 2018.
227. Heidari A, Gobato R, "Putrescine, Cadaverine, Spermine and Spermidine–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules", Parana Journal of Science and Education (PJSE)–v.4, n.5, (1–14) July 1, 2018.
228. Heidari A, "Cadaverine (1,5–Pentanediamine or Pentamethylenediamine), Diethyl Azodicarboxylate (DEAD or DEADCAT) and Putrescine (Tetramethylenediamine) Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Hiv and Sexual Health Open Access Open Journal. 1 (1): 4–11, 2018.

229. Heidari A, "Improving the Performance of Nano–Endofullerenes in Polyaniline Nanostructure–Based Biosensors by Covering Californium Colloidal Nanoparticles with Multi–Walled Carbon Nanotubes", Journal of Advances in Nanomaterials, Vol. 3, No. 1, Pages 1–28, 2018.
230. Gobato R, Heidari A, "Molecular Mechanics and Quantum Chemical Study on Sites of Action of Sanguinarine Using Vibrational Spectroscopy Based on Molecular Mechanics and Quantum Chemical Calculations", Malaysian Journal of Chemistry, Vol. 20 (1), 1–23, 2018.
231. Heidari A, "Vibrational Biospectroscopic Studies on Anti–Cancer Nanopharmaceuticals (Part I)", Malaysian Journal of Chemistry, Vol. 20 (1), 33-73, 2018.
232. Heidari A, "Vibrational Biospectroscopic Studies on Anti–Cancer Nanopharmaceuticals (Part II)", Malaysian Journal of Chemistry, Vol. 20 (1), 74–117, 2018.
233. Heidari A, "Uranocene (U(C8H8)2) and Bis(Cyclooctatetraene)Iron (Fe(C8H8)2 or Fe(COT)2)–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules", Chemistry Reports, Vol. 1, Iss. 2, Pages 1–16, 2018.
234. Heidari A, "Biomedical Systematic and Emerging Technological Study on Human Malignant and Benign Cancer Cells and Tissues Biospectroscopic Analysis under Synchrotron Radiation", Glob Imaging Insights, Volume 3 (3): 1–7, 2018.
235. Heidari A, "Deep–Level Transient Spectroscopy and X–Ray Photoelectron Spectroscopy (XPS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Res Dev Material Sci. 7(2). RDMS.000659, 2018.
236. Heidari A, "C70–Carboxyfullerenes Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Glob Imaging Insights, Volume 3 (3): 1–7, 2018.
237. Heidari A, "The Effect of Temperature on Cadmium Oxide (CdO) Nanoparticles Produced by Synchrotron Radiation in the Human Cancer Cells, Tissues and Tumors", International Journal of Advanced Chemistry, 6 (2): 140–56, 2018.
238. Heidari A, "A Clinical and Molecular Pathology Investigation of Correlation Spectroscopy (COSY), Exclusive Correlation Spectroscopy (ECOSY), Total Correlation Spectroscopy (TOCSY), Heteronuclear Single–Quantum Correlation Spectroscopy (HSQC) and Heteronuclear Multiple–Bond Correlation Spectroscopy (HMBC) Comparative Study on Malignant and Benign Human Cancer Cells, Tissues and Tumors under Synchrotron and Synchrocyclotron Radiations Using Cyclotron versus Synchrotron, Synchrocyclotron and the Large Hadron Collider (LHC) for Delivery of Proton and Helium Ion (Charged Particle) Beams for Oncology Radiotherapy", European Journal of Advances in Engineering and Technology, 5 (7): 414-26, 2018.
239. Heidari A, "Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer

Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", J Oncol Res; 1 (1): 1–20, 2018.

240. Heidari A, "Use of Molecular Enzymes in the Treatment of Chronic Disorders", Canc Oncol Open Access J. 1 (1): 12–5, 2018.
241. Heidari A, "Vibrational Biospectroscopic Study and Chemical Structure Analysis of Unsaturated Polyamides Nanoparticles as Anti–Cancer Polymeric Nanomedicines Using Synchrotron Radiation", International Journal of Advanced Chemistry, 6 (2) 167-89, 2018.
242. Heidari A, "Adamantane, Irene, Naftazone and Pyridine–Enhanced Precatalyst Preparation Stabilization and Initiation (PEPPSI) Nano Molecules", Madridge J Nov Drug Res. 2 (1): 61-7, 2018.
243. Heidari A, "Heteronuclear Single–Quantum Correlation Spectroscopy (HSQC) and Heteronuclear Multiple–Bond Correlation Spectroscopy (HMBC) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Madridge J Nov Drug Res, 2 (1): 68-74, 2018.
244. Heidari A, R. Gobato, "A Novel Approach to Reduce Toxicities and to Improve Bioavailabilities of DNA/RNA of Human Cancer Cells–Containing Cocaine (Coke), Lysergide (Lysergic Acid Diethyl Amide or LSD), Δ^9–Tetrahydrocannabinol (THC) [(–)–trans–Δ^9–Tetrahydrocannabinol], Theobromine (Xantheose), Caffeine, Aspartame (APM) (NutraSweet) and Zidovudine (ZDV) [Azidothymidine (AZT)] as Anti–Cancer Nano Drugs by Coassembly of Dual Anti–Cancer Nano Drugs to Inhibit DNA/RNA of Human Cancer Cells Drug Resistance", Parana Journal of Science and Education (PJSE), v. 4, n. 6, pp. 1–17, 2018.
245. Heidari A, Gobato R, "Ultraviolet Photoelectron Spectroscopy (UPS) and Ultraviolet–Visible (UV–Vis) Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Parana Journal of Science and Education (PJSE), v. 4, n. 6, pp. 18–33, 2018.
246. Gobato R, Heidari A. Mitra, "The Creation of C13H20BeLi2SeSi. The Proposal of a Bio–Inorganic Molecule, Using Ab Initio Methods for the Genesis of a Nano Membrane", Arc Org Inorg Chem Sci 3 (4). AOICS.MS.ID.000167, 2018.
247. Gobato R, Heidari A, "Using the Quantum Chemistry for Genesis of a Nano Biomembrane with a Combination of the Elements Be, Li, Se, Si, C and H", J Nanomed Res.7 (4): 241-52, 2018.
248. Heidari A, "Bastadins and Bastaranes–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules", Glob Imaging Insights, Volume 3 (4): 1–7, 2018.
249. Heidari A, "Fucitol, Pterodactyladiene, DEAD or DEADCAT (DiEthyl AzoDiCArboxylaTe), Skatole, the NanoPutians, Thebacon, Pikachurin, Tie Fighter, Spermidine and Mirasorvone Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Glob Imaging Insights, Volume 3 (4): 1-8, 2018.

250. Dadvar E, Heidari A, "A Review on Separation Techniques of Graphene Oxide (GO)/Base on Hybrid Polymer Membranes for Eradication of Dyes and Oil Compounds: Recent Progress in Graphene Oxide (GO)/Base on Polymer Membranes–Related Nanotechnologies", Clin Med Rev Case Rep 5: 228, 2018.
251. Heidari A, Gobato R, "First–Time Simulation of Deoxyuridine Monophosphate (dUMP) (Deoxyuridylic Acid or Deoxyuridylate) and Vomitoxin (Deoxynivalenol (DON)) ((3α,7α)–3,7,15–Trihydroxy–12,13–Epoxytrichothec–9–En–8–One)–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Parana Journal of Science and Education (PJSE), Vol. 4, No. 6, pp. 46–67, 2018.
252. Heidari A, "Buckminsterfullerene (Fullerene), Bullvalene, Dickite and Josiphos Ligands Nano Molecules Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Hematology and Thromboembolic Diseases Prevention, Diagnosis and Treatment under Synchrotron and Synchrocyclotron Radiations", Glob Imaging Insights, Volume 3 (4): 1-7, 2018.
253. Heidari A, "Fluctuation X–Ray Scattering (FXS) and Wide–Angle X–Ray Scattering (WAXS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Glob Imaging Insights, Volume 3 (4): 1–7, 2018.
254. Heidari A, "A Novel Approach to Correlation Spectroscopy (COSY), Exclusive Correlation Spectroscopy (ECOSY), Total Correlation Spectroscopy (TOCSY), Incredible Natural–Abundance Double–Quantum Transfer Experiment (INADEQUATE), Heteronuclear Single–Quantum Correlation Spectroscopy (HSQC), Heteronuclear Multiple–Bond Correlation Spectroscopy (HMBC), Nuclear Overhauser Effect Spectroscopy (NOESY) and Rotating Frame Nuclear Overhauser Effect Spectroscopy (ROESY) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Glob Imaging Insights, Volume 3 (5): 1-9, 2018.
255. Heidari A, "Terphenyl–Based Reversible Receptor with Rhodamine, Rhodamine–Based Molecular Probe, Rhodamine–Based Using the Spirolactam Ring Opening, Rhodamine B with Ferrocene Substituent, Calix[4]Arene–Based Receptor, Thioether + Aniline–Derived Ligand Framework Linked to a Fluorescein Platform, Mercuryfluor–1 (Flourescent Probe), N,N'–Dibenzyl–1,4,10,13–Tetraraoxa–7,16–Diazacyclooctadecane and Terphenyl–Based Reversible Receptor with Pyrene and Quinoline as the Fluorophores–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules", Glob Imaging Insights, Volume 3 (5): 1–9, 2018.
256. Heidari A, "Small–Angle X–Ray Scattering (SAXS), Ultra–Small Angle X–Ray Scattering (USAXS), Fluctuation X–Ray Scattering (FXS), Wide–Angle X–Ray Scattering (WAXS), Grazing–Incidence Small–Angle X–Ray Scattering (GISAXS), Grazing–Incidence Wide–Angle X–Ray Scattering (GIWAXS), Small–Angle Neutron Scattering (SANS), Grazing–Incidence Small–Angle Neutron Scattering (GISANS), X–Ray Diffraction (XRD), Powder X–Ray Diffraction (PXRD), Wide–Angle X–Ray Diffraction (WAXD), Grazing–

Incidence X–Ray Diffraction (GIXD) and Energy–Dispersive X–Ray Diffraction (EDXRD) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Glob Imaging Insights, Volume 3 (5): 1–10, 2018.

257. Heidari A, "Nuclear Resonant Inelastic X–Ray Scattering Spectroscopy (NRIXSS) and Nuclear Resonance Vibrational Spectroscopy (NRVS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Glob Imaging Insights, Volume 3 (5): 1–7, 2018.
258. Heidari A, "Small–Angle X–Ray Scattering (SAXS) and Ultra–Small Angle X–Ray Scattering (USAXS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation", Glob Imaging Insights, Volume 3 (5): 1–7, 2018.
259. Heidari A, "Curious Chloride (CmCl3) and Titanic Chloride (TiCl4)–Enhanced Precatalyst Preparation Stabilization and Initiation (EPPSI) Nano Molecules for Cancer Treatment and Cellular Therapeutics", J. Cancer Research and Therapeutic Interventions, Volume 1, Issue 1, Pages 01–10, 2018.
260. Gobato R, Gobato MRR, Heidari A, Mitra A, "Spectroscopy and Dipole Moment of the Molecule C13H20BeLi2SeSi via Quantum Chemistry Using Ab Initio, Hartree–Fock Method in the Base Set CC–pVTZ and 6–311G**(3df, 3pd)", Arc Org Inorg Chem Sci 3 (5), Pages 402-9, 2018.
261. Heidari A, "C60 and C70–Encapsulating Carbon Nanotubes Incorporation into the Nano Polymeric Matrix (NPM) by Immersion of the Nano Polymeric Modified Electrode (NPME) as Molecular Enzymes and Drug Targets for Human Cancer Cells, Tissues and Tumors Treatment under Synchrotron and Synchrocyclotron Radiations", Integr Mol Med, Volume 5 (3): 1-8, 2018.
262. Heidari A, "Two–Dimensional (2D) 1H or Proton NMR, 13C NMR, 15N NMR and 31P NMR Spectroscopy Comparative Study on Malignant and Benign Human Cancer Cells and Tissues under Synchrotron Radiation with the Passage of Time", Glob Imaging Insights, Volume 3 (6): 1–8, 2018.
263. Heidari A, "FT–Raman Spectroscopy, Coherent Anti–Stokes Raman Spectroscopy (CARS) and Raman Optical Activity Spectroscopy (ROAS) Comparative Study on Malignant and Benign Human Cancer Cells and Tissues with the Passage of Time under Synchrotron Radiation", Glob Imaging Insights, Volume 3 (6): 1–8, 2018.
264. Heidari A, "A Modern and Comprehensive Investigation of Inelastic Electron Tunneling Spectroscopy (IETS) and Scanning Tunneling Spectroscopy on Malignant and Benign Human Cancer Cells, Tissues and Tumors through Optimizing Synchrotron Microbeam Radiotherapy for Human Cancer Treatments and Diagnostics: An Experimental Biospectroscopic Comparative Study", Glob Imaging Insights, Volume 3 (6): 1–8, 2018.